DUBLIN, Calif.—Eksigent, a developer of advanced low-flow fluid delivery technologies for drug discovery and other life science applications, announced a new distribution agreement with Hong Kong-based Bionoetikos Ltd. The agreement covers sales and service of Eksigent's NanoLC HPLC product line in Taiwan, Indonesia, Philippines, Vietnam, Malaysia, Singapore, Thailand, Laos and Cambodia. Bionoetikos Ltd. is a life science industry consulting and distribution company focusing on Asia. The company has expertise in a range of applications including molecular biology, protein science, bioprocess engineering, agri-biotech, food and beverage and clinical diagnostics.

"The Bioneotikos group is pleased to work with Eksigent, whose technology is clearly a superior solution for front-end sample handling in LC-MS applications for proteomics," says Mark Daniels, managing director of Bionoetikos, Ltd. "The need for advanced proteomics and other drug discovery technologies will continue to grow in Southeast Asia, where healthcare challenges and consciousness are on the rise."

Eksigent's NanoLC-1D and NanoLC-2D proteomics systems incorporate proprietary microfluidic flow control technology to eliminate the need for flow splitting, resulting in high reproducibility and sensitivity with minimal solvent waste. The company recently added MALDI spotting capability to this product line, enabling use of the systems with MALDI or nanospray MS.